

1 Exploring the secretion of immunogenic gluten peptides in breast milk 2 from celiac and non celiac mothers

3 **Ángela Ruiz-Carnicer^{1,†}, Verónica Segura^{1,†}, María de Lourdes Moreno¹, Cristóbal Coronel-
4 Rodríguez², Carolina Sousa¹, and Isabel Comino^{1, *}**

5 ¹Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, 41012
6 Seville, Spain.

7 ²Health Center Amante Laffón, Seville, Spain.

8 †These authors contributed equally to this work and share first authorship.

9 *** Correspondence:**

10 Isabel Comino
11 icomino@us.es

12 **Keywords:** antigens, breast milk; celiac disease; gluten exposure; gluten-free diet; gluten
13 immunogenic peptides.

14

15 **Abstract**

16 **Background:** Exposure to antigens is crucial for child immune system development, aiding disease
17 prevention and promoting infant health. Some common food antigen proteins are found in human
18 breast milk. However, it is unclear whether gluten antigens linked to celiac disease (CD) are transmitted
19 through breast milk, potentially impacting the development of the infant's immune system.

20 **Objective:** This study aimed to analyze the passage of gluten immunogenic peptides (GIP) into human
21 breast milk. We evaluated the dynamics of GIP secretion after lactating mothers adopted a controlled
22 gluten-rich diet.

23 **Methods:** We prospectively enrolled 96 non-CD and 23 CD lactating mothers, assessing total proteins
24 and casein in breast milk, and GIP levels in breast milk and urine. Subsequently, a longitudinal study
25 was conducted in a subgroup of 12 non-CD lactating mothers who adopted a controlled gluten-rich
26 diet. GIP levels in breast milk and urine samples were assayed by multiple sample
27 collections over 96 hours.

28 **Results:** Analysis of a single sample revealed that 24% of non-CD lactating mothers on a regular
29 unrestricted diet tested positive for GIP in breast milk, and 90% tested positive in urine, with
30 significantly lower concentrations in breast milk. Nevertheless, on a controlled gluten-rich diet and the
31 collection of multiple samples, GIP were detected in 75% and 100% of non-CD participants in breast
32 milk and urine, respectively. The transfer dynamics in breast milk samples were long-enduring and
33 GIP secretion persisted from 0 to 72 h. In contrast, GIP secretion in urine samples was limited to the
34 first 24 h, with inter-individual variations. In the cohort of CD mothers, 82.6% and 87% tested negative
35 for GIP in breast milk and urine, respectively.

36 **Conclusions:** This study definitively established the presence of GIP in breast milk, with substantial
37 inter-individual variations in secretion dynamics. Our findings provide insights into distinct GIP
38 kinetics observed in sequentially collected breast milk and urine samples, suggesting differential gluten
39 metabolism patterns depending on the organ or system involved. Future research is essential to
40 understand whether GIP functions as sensitizing or tolerogenic agents in the immune system of
41 breastfed infants.

42 **Introduction**

43 Celiac disease (CD) is a systemic disorders triggered by exposure to dietary gluten in
44 genetically predisposed individuals [1,2]. It is a common disease that can affect individuals of all ages
45 and is characterized by a wide spectrum of clinical manifestations. The symptoms include abdominal
46 pain, bloating, nausea, vomiting, and/or diarrhea. Additionally, extra-intestinal manifestations can
47 occur, such as blistering skin rashes, ataxia, bone disease, and issues in the reproductive and endocrine
48 systems, among others [3].

49 The diagnostic rate for this pathology has increased over the last 10 years [4]. Worldwide
50 epidemiological data show that CD is ubiquitous, with a prevalence of 1.4% [5], and is higher in

51 females than in males [4-8]. The increase in this prevalence may, in part, be attributed to improved
52 recognition and testing of the disease. However, there may also be a real increase in the incidence of
53 this immune disorder, related to environmental factors that promote a loss of tolerance to dietary gluten
54 [9]. Breastfeeding and the timing of gluten introduction have been particularly considered influential
55 factors [10]. Nevertheless, the available evidence regarding the relationship between CD and breast
56 milk remains inconclusive. Extended breastfeeding and, notably, breastfeeding at the time of gluten
57 introduction seem to decrease the risk of developing CD or at least postpone its onset [11,12]. However,
58 conflicting findings persist, as some studies have been unable to establish breastfeeding as protective
59 against the development of CD [13-15].

60 Breastfeeding significantly influences the composition of the intestinal microbiota in the infant
61 and offers substantial potential to prevent allergic diseases [16,17]. The study of breast milk
62 composition is crucial not only for understanding the nutritional requirements of infants, but also for
63 evaluating its impact on neurodevelopment, immune system maturation, and gut development, among
64 others [18]. Additionally, breastfeeding plays a dual role in promoting tolerance through the presence
65 of immunomodulatory substances and facilitating antigen transfer. The presence of food antigens in
66 breast milk is a significant source of early oral exposure that is critical for establishing and reinforcing
67 oral tolerance [19].

68 Common food antigens found in human breast milk include proteins derived from egg
69 (ovalbumin) [20], cow milk (casein and beta-lactoglobulin) [21], and peanuts (arah h1 and arah h2)
70 [22,23]. The frequency and concentration of these dietary proteins in breast milk vary widely among
71 women, with approximately 50% excreting them at concentrations ranging from 0.1 to over 1000 ng/ml
72 [24-26]. However, the presence of certain proteins/peptides including gluten remains unclear [27,28].
73 Gluten proteins have unique properties compared to other dietary proteins. In particular, they contain
74 high proportions of glutamine and proline residues, making them resistant to degradation by

75 gastrointestinal proteases. Consequently, relatively long gluten peptides with intact immunotoxic
76 epitopes accumulate in the lumen of the small intestine and cross the epithelial barrier, ultimately
77 entering the systemic circulation [29-31]. This raises the possibility of their subsequent secretion
78 through the mammary glands into breast milk. Therefore, the possible presence of gluten peptides in
79 breast milk could promote oral tolerance or sensitivity to gluten in breastfed infants.

80 Our research group is a pioneer in identifying and analyzing gluten in human samples. In
81 particular, monoclonal antibodies (moAbs) have been used to develop immunoassays for the sensitive
82 and specific detection of the gluten immunogenic peptides (GIP). These assays have enabled to
83 measure GIP concentrations in human samples, including feces and urine, confirming their absorption
84 into the bloodstream [32-36]. Given their resistance to gastrointestinal digestion, GIP play a key role
85 in triggering immunogenic responses within T cells of individuals diagnosed with CD. However, to
86 date, there have been no studies that confirm the existence of gluten peptides in breast milk and if they
87 are immunogenic. On this basis, the aim of this study is to understand the transfer and secretion
88 dynamics of GIP in breast milk. Initially, we carried out a cross-sectional study to analyze the GIP in
89 breast milk samples within a cohort of mothers with and without CD and assessed total protein and
90 caseins secretion. Secondly, we conducted an exploratory longitudinal clinical study to elucidate the
91 differential kinetics of GIP secretion in human milk and urine by examining non-CD mothers after a
92 controlled gluten-rich diet.

93

94 **Materials and methods**

95

96 **Study design and participants**

97 *Cross-sectional study*

98 This cross-sectional study was conducted between September 2020 and September 2023, and
99 included lactating mothers with and without CD. Potential volunteers were invited to participate via
100 the following official notification: Centro de Salud Amante Laffón (Sevilla, Spain), Federación de
101 Asociaciones de Celíacos de España (FACE), Asociación Provincial de Celíacos de Sevilla
102 (Asprocese) and social networks ([https://celiacos.org/la-universidad-de-sevilla-estudia-la-presencia-](https://celiacos.org/la-universidad-de-sevilla-estudia-la-presencia-de-peptidos-del-gluten-en-la-leche-materna/)
103 [de-peptidos-del-gluten-en-la-leche-materna/](https://celiacos.org/la-universidad-de-sevilla-estudia-la-presencia-de-peptidos-del-gluten-en-la-leche-materna/)).

104 A questionnaire was administered to assess the gestational age of the children at delivery and
105 during sample collection process. Furthermore, mothers with CD were asked about the date of CD
106 diagnosis, results of the last duodenal biopsy study, and serum CD antibodies. The inclusion criteria
107 for the cohort of non-CD mothers were as follows: (1) over 18 years of age; (2) regular gluten
108 consumption; and (3) no prior diagnosis of CD, non-CD gluten sensitivity, food allergies, food
109 intolerances, or other gastrointestinal diseases. The inclusion criteria for the cohort of mothers with
110 CD were as follows: (1) over 18 years of age; (2) breastfeeding mothers previously diagnosed with
111 CD, and (3) all volunteers had followed a gluten-free diet (GFD) for at least 2 years prior to enrolling
112 in the study. The exclusion criteria were as follows: (1) participants with associated pathologies or
113 severe psychiatric diseases; and (2) participants who did not collect the samples properly.

114 This study was conducted in accordance with the principles of the Declaration of Helsinki. The
115 study protocol was approved by the regional research ethics committee (ID/Numbers: 0364-N-20,
116 Comunidad Autónoma de Andalucía, Spain), and written informed consent was obtained from all
117 participants.

118 Detailed instructions were provided to all participants at the beginning of the study. Breast milk
119 and urine samples were consecutively collected from each participant. The parameters analyzed were
120 total protein, casein and GIP level in breast milk, and GIP level in urine.

121

122 *Longitudinal study*

123 A longitudinal study was conducted in a selected subgroup of non-CD mothers who were
124 instructed to complete a two-phase study: (1) an initial 3-day phase with a controlled gluten-rich diet
125 and (2) a second 5-day phase with a strict GFD. During this study, participants were provided with a
126 menu planning with foods rich in gluten (pizza, sandwich, wheat pancakes, pasta, croutons, lasagna,
127 etc.) for the first period, and menus with gluten-free (unprocessed or minimally processed) foods for
128 the second phase (Figure 1). All volunteers collected consecutive urine and milk samples at 0 h during
129 the controlled gluten-rich diet and at 3, 6, 24, 48, 72, and 96 h after the start of the GFD.

130

131 **Milk and urine collection**

132 The participants were instructed to collect 10 mL of mature milk and 5 mL of urine in a sealed
133 sterile container. Mothers expressed the milk samples manually or by pump and immediately froze the
134 milk and urine sample at -20°C until collected by the researchers. Once in the laboratory, the samples
135 were homogenized, and after aliquoting, they were stored at -20°C . To optimize the milk protocol,
136 the following were used: 1) whole breast milk samples, and 2) whey samples obtained by centrifuging
137 an aliquot of the milk sample for 5 min at $8000 \times g$ (removal of fat content and cellular elements that
138 could interfere with immunoassays). To ensure temporal coherence and minimize potential data
139 variations, milk and urine samples were collected consecutively over time.

140

141 **Total protein concentration**

142 The protein concentration in the whole milk and whey was quantified using a Pierce BCA
143 Protein Assay Kit (Thermo Fisher Scientific Inc. Waltham, Massachusetts, USA) adapted to
144 microplates. Briefly, 25 μ L of milk/whey or standard diluted was added to 96-well plates in duplicate.
145 After covering the plates and incubating at 37°C for 30 minutes, optical densities were read at 562 nm
146 in the Multiskan Sky Reader (Thermo Fisher Scientific Inc. Waltham, Massachusetts, USA). Each
147 sample was participants to duplicate analyses on different dates.

148

149 **Casein concentration**

150 The casein concentration in breast milk samples was measured by sandwich-type enzyme-
151 linked immunosorbent assay (ELISA) using the AlerTox ELISA Casein Kits (AlerTox ELISA,
152 Hygiena Diagnostic España S.L., Seville, Spain), following the manufacturer's guidelines with minor
153 modifications. Briefly, breast milk samples were incubated for 15 min at 60°C with gentle agitation in
154 extraction buffer and centrifuged. ELISA was performed using a microtiter plate and standards
155 previously diluted 1:100. The samples were then incubated with a casein-conjugated antibody for 20
156 min. The TMB casein substrate solution was then added. Colour development was stopped with a stop
157 solution of casein, and absorbance at 450 nm was measured using a Multiskan Sky Reader microplate
158 reader (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA). A minimum of two separate
159 aliquots from each sample were examined on different days.

160

161 **Determination of GIP in milk and urine samples**

162 Milk and urine samples were processed according to the guidelines provided by the
163 manufacturer (iVYCHECK GIP Urine based on G12 and A1 moAbs; Biomedal S.L., Seville, Spain).

164 Subsequently, 100 μ L of each sample was applied to the detection test strip. After a 30-minute
165 incubation period, the immunochromatographic strip was assessed using a lateral flow test reader
166 cassette. The limit of detection (LoD) was established through visual examination (2.25 ng GIP /mL),
167 and the measuring range was 3.12-25 ng GIP /mL that was determined using the iVYCHECK Reader
168 (Biomedal S.L.). Each sample was run in duplicate, and at least two different aliquots of each sample
169 were tested on different days.

170

171 **Statistical Analysis**

172 The results of the quantitative variables were expressed using the median and interquartile
173 range (IQR), and those of the qualitative variables were expressed as percentages. The goodness-of-fit
174 to normality was calculated using the Shapiro–Wilk test.

175 The Mann–Whitney U test was used to compare quantitative variables in independent groups,
176 and the Wilcoxon signed-rank test was used to compare quantitative variables in dependent groups.
177 The McNemar test was used to compare qualitative variables within dependent groups. For all the
178 cases, $P < 0.05$ was considered statistically significant. The data analysis was performed using SPSS
179 26.0 software for Windows (SPSS Inc.).

180

181 **Results**

182

183 **Participants**

184 We recruited 96 non-CD lactating mothers taking a normal unrestricted diet with a median age
185 of 35 (IQR: 32-37) and 23 CD lactating mothers under long-term GFD with a median age of 35 (IQR:

186 31-37). In non-CD mothers, the mode of delivery of the fetus was: 81% (78/96) vaginal and, 17%
187 (16/96) cesarean. For CD mothers, the mode of delivery of the fetus was: 17% (4/23) vaginal and, 4%
188 (1/23) cesarean. The gestational age, 40 (IQR: 39-40) weeks, was similar in both cohorts. However,
189 the median of the baby's age was 2 (IQR:1-5) months in non-CD mothers and 8 (IQR: 4-20) months
190 in CD-mothers.

191

192 **Cross-sectional study**

193 As this was a non-interventional study, and neither the amount of fluid ingested, nor the feeding
194 pattern of the lactating mothers was modified. Additionally, urine and breast milk samples were
195 collected only once.

196 *Determination of total protein and casein in breast milk*

197 To evaluate whether differences in the diets of non-CD and CD mothers could affect the protein
198 content of their breast milk, we analyzed protein concentrations before and after whey separation. The
199 protein concentration was higher in whole milk than in whey in both cohorts (Wilcoxon test, $P < 0.001$)
200 (Figure 2A). In CD mothers, the median was 9.7 (IQR= 9.1-12.8) and 9 mg/mL (IQR =8-11) for whole
201 breast milk and whey samples, respectively, while in non-CD mothers was 10.7 (IQR= 9.7-12) and 9.8
202 mg/mL (IQR=8.6-11.6). Protein levels values were similar between the study cohorts, with no
203 significant differences (Mann–Whitney U test, $P=0.273$).

204 Bovine casein is one of the non-human proteins most frequently found in human breast milk
205 [21,37,38]. In this study, casein was detected in 78.15% of the samples (93/119) (Figure 2B),
206 specifically 65% (16/23) in the cohort of CD mothers and 79% (76/96) in non-CD mothers (median
207 62.5 ng/mL; IQR 50–76 and median 60.7 ng/mL; IQR 52.2–73.4, respectively). As expected, the

208 results showed no significant differences between the bovine casein values of the control and CD
209 mothers (Mann–Whitney U test, $P=0.797$) (Figure 2C).

210 *Determination of GIP in breast milk*

211 We investigated the presence of gluten in breast milk by quantifying GIP using specific moAbs
212 (G12/A1). In the cohort of non-CD mothers without gluten restriction in their diet, 24% (23/96) of
213 breast milk samples contained detectable levels of GIP. There were no significant differences in the
214 GIP levels of whole milk and whey for these mothers. Urine samples tested positive for GIP in 90%
215 (86 out of 96) of volunteers within this cohort. The milk and urine samples were collected
216 consecutively over time, and our findings revealed that the concentrations of GIP in the milk were
217 significantly lower than those in the urine (average range according to the Mann–Whitney U test: 60.71
218 and 132.39, respectively) ($P < 0.001$) (Figure 3). However, 96% (22/23) of mothers who tested positive
219 in breast milk also had a GIP positive result in urine.

220 In the cohort of CD mothers, 82.6% (19/23) tested negative for GIP in breast milk. GIP was
221 detected in only four breast milk samples and three urine samples from 23 participants, and one of the
222 participants showed positive results for both samples. No significant differences were found between
223 the GIP values of the milk and urine samples ($P > 0.05$).

224 These results suggest the presence of GIP across both biological fluids, albeit at varying levels,
225 underscoring the importance of comprehensive assessment methods in elucidating GIP dynamics in
226 lactating mothers with CD.

227

228 **Longitudinal study**

229 *Kinetics of GIP secretion in breast milk*

230 A parallel longitudinal descriptive study was conducted using a subgroup of 12 volunteers from
231 the cohort of non-CD mothers. This study aimed to elucidate GIP kinetics in breast milk after maternal
232 ingestion of gluten. For this purpose, all volunteers were instructed to complete a two-phase study:
233 phase 1 on a controlled gluten-rich diet, and phase 2 on a strict GFD. GIP levels were quantified in
234 breast milk and urine samples taken at various time points, from 0 to 96 h after gluten ingestion and at
235 the onset of the GFD.

236 The results were GIP positive in 75% (9/12) of the participants in breast milk samples and 100%
237 (12/12) of the urine samples (Figure 4), considering at least one positive sample per participant. After
238 adopting a gluten-rich diet (0 h), 54.5% (6/11) of the volunteers tested positive for GIP in their breast
239 milk. At 3 and 6 h from the beginning of the GFD, GIP was detected in 33.3% (4/12) and 16.7% (2/12)
240 of the volunteers, respectively. In addition, we found positive GIP in breast milk on the following
241 hours: at 24, 48 and 72 h in 16.7% (2/12), 25% (3/12) and 8.3% (1/12) of the participants, respectively.
242 The means GIP values detected in breast milk were similar between 0 and 48 h, however, significant
243 differences were found after 72 h ($P < 0.05$) (Figure 5A). No GIP was detected in breast milk after 72 h
244 in the volunteers studied. However, the period of GIP excretion in urine after the start of GFD is limited
245 to the first 24 h (100% of urine samples at 0h, 92% at 3 and 6 h, and 17% at 24 h) (Figure 5B).

246

247 **Discussion**

248

249 To our knowledge, this study represents the first instance of identifying immunogenic gluten
250 peptides in breast milk samples. The presence of GIP in breast milk indicates that gluten is absorbed
251 through the intestinal mucosa, enters the bloodstream, and is subsequently secreted by the mammary
252 gland. The detection of measurable amounts of GIP in breast milk suggests that infants are exposed to

253 gluten antigens before their introduction into the diet, which could potentially impact CD development
254 and other gluten-related disorders.

255 Our findings reveal that the secretion of GIP in breast milk exhibits dynamic and fluctuating
256 changes over time, likely influenced by various factors such as maternal diet, hormonal fluctuations,
257 and the feeding patterns of the infant, among others. This dynamic nature underscores the inherent
258 complexity involved in studying GIP in breast milk. Following a gluten-containing diet challenge and
259 the collection of multiple breast milk samples (ensuring at least one positive sample from each
260 participant), the percentage of GIP-positive participants was to 75%. The secretion kinetics extended
261 from 0 to 72 hours after the gluten-containing diet challenge and the commencement of the GFD. It is
262 important to note that a considerable degree of intra- and interindividual variation was observed in the
263 secretion of GIP, as previously reported for other food antigens [39-42].

264 Chirido et al. [28] detected undegraded gliadins in all milk samples analyzed from lactating
265 mothers following a normal diet, using a polyclonal antibody. The concentrations of gliadins observed
266 exceeded those reported in our study to immunogenic gluten peptides. These variations may be
267 attributed to differences in the study populations, the identified epitopes, and the specificity of the
268 antibodies. The polyclonal antibodies are produced from a mixture of different immune cells, and they
269 may bind to unrelated proteins, causing cross-reactivity. This cross-reactivity can lead to false signals
270 or interference in assays. In contrast, our study has the advantage of detecting GIP using G12 and A1
271 moAbs, known for their reactivity with tandem epitopes contained in the major immunogenic peptides
272 associated with CD [36,43].

273 As expected, in the cohort of mothers with CD on a GFD, the majority of the breast milk
274 samples (82.6%, 19/23) tested negative for GIP. Only four breast milk samples tested positive for GIP.
275 Although the mothers with CD in our study followed a GFD, the possibility of dietary lapses cannot

276 rule out. A GFD is difficult to maintain, and adult patients with CD consume unsafe amounts of gluten
277 on average [44-46]. Therefore, these results may be attributed to possible transgressions in the GFD as
278 no food intake control was implemented for mothers with CD.

279 Understanding how other proteins manifest in breast milk is fundamental it provides crucial
280 insights into the composition of breast milk and its role in infant nutrition and development. In our
281 study, no significant differences were detected in the total protein levels in breast milk between non-
282 CD and CD mothers. Thus, our findings suggest that a GFD does not influence variations in the levels
283 of this macronutrient in breast milk. These results agree with those of prior studies that have
284 demonstrated a remarkable consistency in the macronutrient composition of breast milk across
285 different populations despite potential variations in maternal nutritional status [47]. With respect to
286 food antigens, we also proved the transference of bovine casein into breast milk that represents one of
287 the most commonly secreted non-human proteins [21]. The levels of this protein in breast milk were
288 in the ng/mL range, similar to those of GIP and other food antigens [48]. No significant statistical
289 differences in bovine casein levels were observed between the non-CD and CD cohorts. This result
290 was expected, given that cow milk proteins are not only present in dairy products and their derivatives,
291 but are also widely incorporated into a myriad of manufactured items such as bread, cold cuts, sausages,
292 frozen fish, sweeteners, preserves, and medicines. Additionally, numerous additives used in the food
293 industry are derived from milk [49].

294 The transfer of proteins from the maternal intestinal tract to the mammary gland is not yet well
295 understood [24,48,50-52]. Additionally, food proteins secreted into the breast milk appear at highly
296 variable concentrations at different time points following exposure and in different forms, either as free
297 proteins or as components of immune complexes [24]. This makes it impossible to precisely predict
298 the concentration at which food antigens/allergens will appear in breast milk and their impact on the
299 immune response of the breast-fed children. For example, ovalbumin was detected in 68% of breast

300 milk samples following egg ingestion, while beta-lactoglobulin was found in 62.5% of lactating women
301 after consuming cow milk, exhibiting variable appearance and disappearance over a 15-hour sampling
302 period. Another study observed the presence of beta-lactoglobulin in breast milk up to 7 days after oral
303 intake of cow's milk [37]. Kinetic analysis of peanut protein transfer into breast milk revealed that 11
304 out of 23 mothers excreted peanut proteins, with 73% showing appearance within 1 hour of ingestion.
305 In this work, in a cohort of non-CD mothers, taking a single sample of breast milk and urine
306 consecutively over time, we have demonstrated that the percentage of GIP- positive milk samples was
307 significantly lower as compared to urine samples. The detection of GIP in the urine of 90% of non-CD
308 mothers implied that the vast majority of volunteers in this cohort consumed gluten; however, this
309 gluten intake was not reflected in breast milk (with only 24% breast milk being GIP positive). To
310 understand this differential excretion/secretion GIP pattern between urine and breast milk and the
311 excretion kinetics of gluten peptides in breast milk we designed a two-phase longitudinal trial: phase
312 1 involved a gluten-rich diet by menu planning, and phase 2 enforced a strict GFD. We measured GIP
313 levels in the breast milk at various time points, ranging from 0 to 96 h after gluten ingestion and at the
314 commencement of a GFD. The period of GIP excretion in urine after initiating the GFD was confined
315 to the initial 24 h, with 100% of the volunteers testing positive for GIP during this period. In contrast,
316 the period of GIP secretion in breast milk was extended to 72 h, with 75% of volunteers showing
317 positive GIP results. This result confirmed the differential kinetics of GIP in breast milk and urine
318 samples collected sequentially.

319 Gluten proteins are initially digested by the enzymes in the mother's intestinal tract. However,
320 this digestion is often incomplete, leaving behind resistant peptides that can cross the intestinal barrier.
321 It is probable that these peptides reach the mammary glands throughout the entire lactation process.
322 We hypothesize that these peptides may undergo partial degradation before being secreted into the
323 mammary glands, potentially extending the time of secretion. Consequently, the mammary gland could

324 serve as a reservoir for certain proteins, including gluten. This speculation arises from observations
325 that mothers who followed the same diet, with menu planning, exhibited fluctuating gluten secretion
326 and interindividual differences.

327 In this longitudinal trial, the children were breastfed during the milk sample collection period,
328 and this may limit the scope of our results. It should be noted that not all breast milk samples could be
329 collected within the designated 0 to 96 h timeframe, and GIP could have been secreted in some
330 uncollected milk samples. Pooled 24h milk samples are generally considered gold standards for
331 collection; however, they are not possible if the mother wants to maintain normal breastfeeding
332 behaviors [42]. Furthermore, it is likely that the variations in the rate and concentration at which gluten
333 is secreted into breast milk can be attributed to the complexity and content of meals consumed before
334 or after gluten intake within our study group, and this could also contribute to the variations observed.

335 Our findings provide a conclusive demonstration of the presence of GIP in breast milk. Notable
336 aspects of this study include the analysis of breast milk samples and the sequential analysis of urine
337 samples using a specific assay designed for detecting GIP, coupled with the collection of multiple
338 samples over several days. We now have the molecular tool to further investigate whether and how
339 GIP are processed and secreted into breast milk. This investigation has raised important questions
340 about the role that these proteins may play in the development of the immune system of infants,
341 particularly considering that exposure to gluten in children occurs before the introduction of
342 complementary feeding, as was previously understood. Therefore, future studies are necessary to know
343 whether GIP act as sensitizing or tolerogenic agents in the immune system of breastfed babies.

344 **Figures**

345

A

	DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4
Breakfast	Toast GCD	Toast GCD	Toast GCD	Coffee / Fruit/Greek natural yogurt GFD	Coffee / Fruit/Greek natural yogurt GFD	Coffee / Fruit/Greek natural yogurt GFD	Coffee / Fruit/Greek natural yogurt GFD
Lunch	Pasta/Bread or Cronfons/ lasagna GCD	Pasta/Bread or Cronfons/ lasagna GCD	<ul style="list-style-type: none"> ▪ Ratatouille GFD ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Lentils GFD ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Grilled tuna GFD ▪ Dressing with fish eggs ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Baked chicken GFD ▪ Bonito in marinade ▪ Fruit/Greek natural yogurt 	
Dinner	Pizza/Sadwich/Wheat pancakes GCD	Pizza/Sadwich/Wheat pancakes GCD	<ul style="list-style-type: none"> ▪ Omelette GFD ▪ Salad ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Octopus marinade GFD ▪ Chicken ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Garlic chicken GFD ▪ Fruit/Greek natural yogurt 	<ul style="list-style-type: none"> ▪ Grilled mushrooms GFD ▪ Fruit/Greek natural yogurt 	


B

DAY -2	DAY -1	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4
		<p><u>Collection of breast milk and urine samples:</u></p> <p>1*) After breakfast</p> <p>2*) 3 hours after the 1st sample</p> <p>3*) 6 hours after the 1st sample</p>	<p><u>Collection of breast milk and urine samples:</u></p> <p>1 sample at 24 hours from the 1st sample</p>	<p><u>Collection of breast milk and urine samples:</u></p> <p>1 sample at 48 hours from the 1st sample</p>	<p><u>Collection of breast milk and urine samples:</u></p> <p>1 sample at 72 hours from the 1st sample</p>	<p><u>Collection of breast milk and urine samples:</u></p> <p>1 sample at 96 hours from the 1st sample</p>

346


347 **Figure 1. Menu planning and sample collection planning.** (A) Menu planning with foods rich in
 348 gluten and menus with gluten-free. (B) Sample collection planning. GCD, gluten-containing diet; GFD,
 349 gluten-free diet.

350




351


352 **Figure 2. Total proteins and bovine caseins in breast milk.** (A) Total protein content (mg/mL) in
353 breast milk and whey (milk serum) of non-CD and CD mothers; (B) percentage of non-CD and CD
354 mothers with casein in breast milk; (C) casein concentration in non-CD and CD mothers. Differences
355 between groups were tested with a Wilcoxon signed-rank test in dependent groups and Mann–Whitney
356 U test in independent groups. CD, celiac disease; LoQ, limit of quantification.



357

358 **Figure 3. Detection and quantification of GIP in urine and breast milk of non-CD mothers and**
359 **CD mothers.** n = 96 (non-CD mothers), n = 23 (CD mothers). The data points include 2 values per
360 volunteer. Differences in GIP levels in breast milk and urine between the 2 groups were tested with a
361 Mann–Whitney U test. CD, celiac disease; GIP, gluten immunogenic peptides; LoD, limit of detection;
362 LoQ, limit of quantification; ND, not detectable.





368

369 **Figure 5. Comparison of GIP levels in breast milk and urine of 12 non-CD mothers on a GFD**
370 **for over 96 h after gluten ingestion. (A) GIP secretion in breast milk; (B) GIP excretion in urine.**
371 Comparative analysis via the McNemar test of GIP levels before and after consumption of gluten. GIP,
372 gluten immunogenic peptides; LoD, limit of detection.

373

374 **Conflict of Interest**

375 The authors declare that the research was conducted in the absence of any commercial or financial
376 relationships that could be construed as a potential conflict of interest.

377

378 **Author Contributions**

379 Conceptualization, Á.R.-C., V.S., and I.C.; data curation, Á.R.-C and V.S.; formal analysis, Á.R.-C
380 and V.S; investigation, Á.R.-C., V.S., M.d.L.M., C.C.-R., C.S. and I.C.; methodology, Á.R.-C., V.S.,
381 and I.C; resources, Á.R.-C., V.S., and I.C; writing—original draft, Á.R.-C., V.S., C.S. and I.C;
382 writing—review and editing, Á.R.-C., V.S., M.d.L.M., C.C.-R., C.S. and I.C. All authors have read
383 and agreed to the published version of the manuscript.

384

385 **Funding**

386 This work was supported by grant from Consejería de Economía y Conocimiento, Junta de Andalucía
387 (project P18-RT-3004) PAIDI 2018.

388

389 **Acknowledgments**

390 We would like to thank the Federation of Celiac Associations of Spain (FACE) and the Provincial
391 Association of Celiacs of Seville (Asprocese) for their outreach to the population, as well as the
392 volunteer mothers who enrolled in the study.

393

394 **Reference**

- 395 1. Al-Toma, A., Volta, U., Auricchio, R., Castillejo, G., Sanders, D. S., Cellier, C., et al (2019). European
396 Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related
397 disorders. *United European Gastroenterol. J.* 7(5):583–613. doi: 10.1177/2050640619844125.
- 398 2. Besser, HA., Khosla, C (2023). Celiac disease: mechanisms and emerging therapeutics. *Trends*
399 *Pharmacol. Sci.* 44(12):949-962. doi: 10.1016/j.tips.2023.09.006.
- 400 3. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al (2019). Celiac disease: a
401 comprehensive current review. *BMC Med.* 17(1):142. doi: 10.1186/s12916-019-1380-z.

- 402 4. King, JA., Jeong, J., Underwood, FE., Quan, J., Panaccione, N., Windsor, JW., et al (2020). Incidence
403 of celiac disease is increasing over time: a systematic review and meta-analysis. *Am. J. Gastroenterol.*
404 115(4), 507–525. doi: 10.14309/ajg.0000000000000523.
- 405 5. Singh, P., Arora, A., Strand, TA., Leffler, DA., Catassi, C., Green, PH., et al (2018). Global prevalence
406 of celiac disease: systematic review and meta-analysis. *Clinical gastroenterology and hepatology: the*
407 *official clinical practice journal of the American Gastroenterological Association*, 16(6), 823–836.e2.
408 <https://doi.org/10.1016/j.cgh.2017.06.037>.
- 409 6. Mardini, HE., Westgate, P., Grigorian, AY (2015). Racial differences in the prevalence of celiac disease
410 in the us population: national health and nutrition examination survey (NHANES) 2009-2012. *Dig. Dis.*
411 *Sci.* 60(6):1738-1742. doi: 10.1007/s10620-014-3514-7.
- 412 7. Lebwohl, B., Green, PHR., Söderling, J., Roelstraete, B., Ludvigsson, JF (2020). Association between
413 celiac disease and mortality risk in a swedish population. *JAMA.* 323(13), 1277–1285. doi:
414 10.1001/jama.2020.1943.
- 415 8. Ludvigsson, JF., Murray, JA (2019). Epidemiology of celiac disease. *Gastroenterol. Clin. North Am.*
416 48(1):1-18. doi:10.1016/j.gtc.2018.09.004.
- 417 9. Lebwohl, B., Rubio-Tapia, A (2021). Epidemiology, presentation, and diagnosis of celiac disease.
418 *Gastroenterology.* 160(1):63-75. doi:10.1053/j.gastro.2020.06.098.
- 419 10. Villamil, E., Rodríguez-Camejo, C., Puyol, A., Fazio, L., Colistro, V., Hernández, A (2021). Immune
420 profiling of breast milk from mothers with treated celiac disease. *Pediatr. Res.* 89(3):488-495.
421 doi:10.1038/s41390-020-0901-y.
- 422 11. Akobeng, AK., Ramanan, AV., Buchan, I., Heller, RF (2006). Effect of breast feeding on risk of coeliac
423 disease: a systematic review and meta-analysis of observational studies. *Arch. Dis. Child.* 91(1):39-43.
424 doi:10.1136/adc.2005.082016.
- 425 12. Aronsson, CA., Agardh, D (2023). Intervention strategies in early childhood to prevent celiac disease-
426 a mini-review. *Front. Immunol.* 14:1106564. doi:10.3389/fimmu.2023.1106564.
- 427 13. Lionetti, E., Castellaneta, S., Francavilla, R., Pulvirenti, A., Tonutti, E., Amarri, S., et al (2014).
428 Introduction of gluten, HLA status, and the risk of celiac disease in children. *N Engl. J. Med.*
429 371(14):1295-1303. doi:10.1056/NEJMoa1400697.
- 430 14. Vriezinga, SL., Auricchio, R., Bravi, E., Castillejo, G., Chmielewska, A., Crespo-Escobar, P., et al
431 (2014). Randomized feeding intervention in infants at high risk for celiac disease. *N. Engl. J. Med.*
432 371(14):1304-15. doi:10.1056/NEJMoa1404172.
- 433 15. Silano, M., Agostoni, C., Sanz, Y., Guandalini, S (2016). Infant feeding and risk of developing celiac
434 disease: a systematic review. *BMJ Open.* 6(1):e009163. doi:10.1136/bmjopen-2015-009163.
- 435 16. Borba, V., Sharif, K., Shoenfeld, Y (2018). Breastfeeding and autoimmunity: Programing health from
436 the beginning. *Am. J. Reprod. Immunol.* 79(1). doi:10.1111/aji.12778.

- 437 17. van den Elsen, LWJ., Garssen, J., Burcelin, R., Verhasselt, V (2019). shaping the gut microbiota by
438 breastfeeding: the gateway to allergy prevention? *Front. Pediatr.* 7:47. doi:10.3389/fped.2019.00047.
- 439 18. Samuel, TM., Zhou, Q., Giuffrida, F., Munblit, D., Verhasselt, V., Thakkar, SK (2020). Nutritional and
440 Non-nutritional Composition of Human Milk Is Modulated by Maternal, Infant, and Methodological
441 Factors. *Front. Nutr.* 7:576133. doi: 10.3389/fnut.2020.576133.
- 442 19. Nuzzi, G., Di Cicco, ME., Peroni, DG (2021). Breastfeeding and allergic diseases: What's new?
443 *Children (Basel)*. 8(5):330. doi:10.3390/children8050330.
- 444 20. Kosmeri, C., Rallis, D., Kostara, M., Siomou, E., Tsabouri, S (2022). Characteristics of exogenous
445 allergen in breast milk and their impact on oral tolerance induction. *Front. Pediatr.* 10:830718.
446 doi:10.3389/fped.2022.830718.
- 447 21. Franco, C., Fente, C., Sánchez, C., Lamas, A., Cepeda, A., Leis, R., et al (2022). Cow's milk antigens
448 content in human milk: a scoping review. *Foods*. 11(12):1783. doi:10.3390/foods11121783.
- 449 22. Bernard, H., Ah-Leung, S., Drumare, MF., Feraudet-Tarisse, C., Verhasselt, V., Wal, JM., et al (2014).
450 Peanut allergens are rapidly transferred in human breast milk and can prevent sensitization in mice.
451 *Allergy*. 69(7):888-897. doi:10.1111/all.12411.
- 452 23. Vadas, P., Wai, Y., Burks, W., Perelman, B (2001). Detection of peanut allergens in breast milk of
453 lactating women. *JAMA*. 285(13):1746-1748. doi:10.1001/jama.285.13.1746.
- 454 24. Macchiaverni, P., Tulic, MK., Verhasselt, V (2013). "Antigens in breast milk: possible impact on
455 immune system education". In *Handbook of dietary and nutritional aspects of human breast milk*.
456 Leiden, The Netherlands: Wageningen Academic. 5:447-460. doi: 10.3920/978-90-8686-764-6_25.
- 457 25. Palmer, DJ., Gold, MS., Makrides, M (2005). Effect of cooked and raw egg consumption on ovalbumin
458 content of human milk: a randomized, double-blind, cross-over trial. *Clin Exp Allergy*. 35(2):173-178.
459 doi:10.1111/j.1365-2222.2005.02170.x
- 460 26. Fukushima, Y., Kawata, Y., Onda, T., Kitagawa, M (1997). Consumption of cow milk and egg by
461 lactating women and the presence of beta-lactoglobulin and ovalbumin in breast milk. *Am. J. Clin. Nutr.*
462 65(1):30-35. doi:10.1093/ajcn/65.1.30.
- 463 27. Troncone, R., Scarcella, A., Donatiello, A., Cannataro, P., Tarabuso, A., Auricchio, S (1987). Passage
464 of gliadin into human breast milk. *Acta Paediatr. Scand.* 76(3):453-456. doi:10.1111/j.1651-
465 2227.1987.tb10498.x
- 466 28. Chirido, FG., Rumbo, M., Añón, MC., Fossati, CA (1998). Presence of high levels of non-degraded
467 gliadin in breast milk from healthy mothers. *Scand. J. Gastroenterol.* 33(11):1186-1192.
468 doi:10.1080/00365529850172557.
- 469 29. Shan, L., Molberg, Ø., Parrot, I., Hausch, F., Filiz, F., Gray, GM., et al (2002). Structural basis for gluten
470 intolerance in celiac sprue. *Science*. 297(5590):2275-2279. doi:10.1126/science.1074129

- 471 30. Heyman, M., Abed, J., Lebreton, C., Cerf-Bensussan, N (2012). Intestinal permeability in coeliac
472 disease: insight into mechanisms and relevance to pathogenesis. *Gut*. 61(9):1355-1364.
473 doi:10.1136/gutjnl-2011-300327.
- 474 31. Palanski, BA., Weng, N., Zhang, L., Hilmer, AJ., Fall, LA., Swaminathan, K., et al (2022). An efficient
475 urine peptidomics workflow identifies chemically defined dietary gluten peptides from patients with
476 celiac disease. *Nature communications*, 13(1), 888. doi:10.1038/s41467-022-28353-1.
- 477 32. Comino, I., Real, A., Vivas, S., Síglez, M.Á., Caminero, A., Nistal, E., et al (2012). Monitoring of gluten-
478 free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.
479 *Am. J. Clin. Nutr.* 95(3):670-677. doi:10.3945/ajcn.111.026708.
- 480 33. Comino, I., Fernández-Bañares, F., Esteve, M., Ortigosa, L., Castillejo, G., Fombuena, B., et al (2016).
481 Fecal gluten peptides reveal limitations of serological tests and food questionnaires for monitoring
482 gluten-free diet in celiac disease patients. *Am. J. Gastroenterol.* 111:1456–65.
483 doi:10.1038/ajg.2017.110.
- 484 34. Comino, I., Segura, V., Ortigosa, L., Espín, B., Castillejo, G., Garrote, J.A., et al (2019). Prospective
485 longitudinal study: Use of faecal gluten immunogenic peptides to monitor children diagnosed with
486 coeliac disease during transition to a gluten-free diet. *Aliment. Pharmacol. Ther.* 49:1484–1492.
487 doi:10.1111/apt.15277.
- 488 35. Moreno, MdeL., Cebolla, Á., Muñoz-Suano, A., Carrillo-Carrion, C., Comino, I., Pizarro, Á., et al
489 (2017). Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals
490 transgressions in the gluten-free diet and incomplete mucosal healing. *Gut*. 66:250-257.
491 doi:10.1136/gutjnl-2015-310148
- 492 36. Ruiz-Carnicer, Á., Garzón-Benavides, M., Fombuena, B., Segura, V., García-Fernández, F., Sobrino-
493 Rodríguez, S., et al (2020). Negative predictive value of the repeated absence of gluten immunogenic
494 peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-
495 up in celiac disease. *Am. J. Clin. Nutrition.* 112(5), 1240–1251. doi:10.1093/ajcn/nqaa188.
- 496 37. Picariello, G., De Cicco, M., Nocerino, R., Paparo, L., Mamone, G., Addeo, F., et al (2019). Excretion
497 of dietary cow's milk derived peptides into breast milk. *Front. Nutr.* 6:25. doi:10.3389/fnut.2019.00025.
- 498 38. Dekker, P. M., Boeren, S., Wijga, A. H., Koppelman, G. H., Vervoort, J. J. M., & Hettinga, K. A. (2020).
499 Maternal Allergy and the Presence of Nonhuman Proteinaceous Molecules in Human Milk. *Nutrients*,
500 12(4), 1169. <https://doi.org/10.3390/nu12041169>.
- 501 39. Daly, SE., Di Rosso, A., Owens, RA., Hartmann, PE (1993). Degree of breast emptying explains
502 changes in the fat content, but not fatty acid composition, of human milk. *Exp. Physiol.* 78(6):741-755.
503 doi:10.1113/expphysiol.1993.sp003722.
- 504 40. Ruel, MT., Dewey, KG., Martínez, C., Flores, R., Brown, KH (1997). Validation of single daytime
505 samples of human milk to estimate the 24-h concentration of lipids in urban Guatemalan mothers. *Am.*
506 *J. Clin. Nutr.* 65(2):439-44.

- 507 41. Kent, JC., Mitoulas, LR., Cregan, MD., Ramsay, DT., Doherty, DA., Hartmann, PE (2006). Volume
508 and frequency of breastfeedings and fat content of breast milk throughout the day. *Pediatrics*.
509 117(3):e387-395. doi:10.1542/peds.2005-1417
- 510 42. Keikha, M., Bahreynian, M., Saleki, M., Kelishadi, R (2017). Macro- and micronutrients of human milk
511 composition: are they related to maternal diet? A comprehensive systematic review. *Breastfeed Med*.
512 12(9):517-527. doi:10.1089/bfm.2017.0048
- 513 43. Morón, B., Bethune, MT., Comino, I., Manyani, H., Ferragud, M., López, MC., et al Toward the
514 assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main
515 immunogenic gluten peptide. *PLoS One*. 2008;3(5):e2294.
- 516 44. Silvester, JA., Comino, I., Kelly, CP., Sousa, C., Duerksen, DR., DOGGIE BAG Study Group. (2020).
517 Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten.
518 *Gastroenterology*, 158(5):1497–1499.e1. doi:10.1053/j.gastro.2019.12.016.
- 519 45. Silvester, JA., Comino, I., Rigaux, LN., Segura, V., Green, KH., Cebolla, A., et al (2020). Exposure
520 sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on
521 a gluten-free diet. *Aliment. Pharmacol. Ther.* 52(9):1469–1479. doi:10.1111/apt.16075.
- 522 46. Wieser, H., Ruiz-Carnicer, Á., Segura, V., Comino, I., Sousa, C. (2021). Challenges of Monitoring the
523 gluten-free diet adherence in the management and follow-up of patients with celiac disease. *Nutrients*.
524 13(7):2274. doi:10.3390/nu13072274
- 525 47. Fields, DA., Demerath, EW (2013). Human milk composition: nutrients and bioactive factors. *Pediatr*.
526 *Clin. North Am.* 60(1):49-74.
- 527 48. Schocker, F., Jappe, U (2022). Breastfeeding: maternally transferred allergens in breast milk: protective
528 or sensitizing? *Mol. Nutr. Food Res.* 66(15):e2200066. doi:10.1002/mnfr.202200066.
- 529 49. Al-Beltagi, M., Saeed, NK., Bediwy, AS., Elbeltagi, R (2022). Cow's milk-induced gastrointestinal
530 disorders: From infancy to adulthood. *World J. Clin. Pediatr.* 11(6):437-454.
531 doi:10.5409/wjcp.v11.i6.437.
- 532 50. Benn, CS., Böttcher, MF., Pedersen, BV., Filteau, SM., Duchén, K (2004). Permeabilidad paracelular
533 epitelial mamaria en madres atópicas y no atópicas versus atopía infantil. *Pediatra. Inmunol. alérgico*.
534 15:123-126.
- 535 51. Monjes, J., Neville, MC (2004). Transcitosis de albúmina a través del epitelio de la glándula mamaria
536 del ratón lactante. *J. Physiol.* 560:267–280.
- 537 52. Pastor-Vargas, C., Maroto, AS., Díaz-Perales, A., Villaba, M., Diaz, NC., Vivanco, F, et al (2015).
538 Sensitive detection of major food allergens in breast milk: first gateway for allergenic contact during
539 breastfeeding. *Allergy*. 70(8):1024-1027. doi:10.1111/all.12646.

540

541

542

543

544

545